Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07226557 · ClinicalTrials.gov registry record

Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation

A clinical trial of Antimicrobial Drug Resistance and Carbapenem Resistant Bacterial Infection, sponsored by National Institutes of Health Clinical Center (CC).

Active
Registry status
5,000
Enrollment target
1
Study location

NCT07226557 is a study of Antimicrobial Drug Resistance and Carbapenem Resistant Bacterial Infection that is active but no longer recruiting, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 5,000 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07226557, a study of Antimicrobial Drug Resistance and Carbapenem Resistant Bacterial Infection, is active but no longer recruiting, sponsored by National Institutes of Health Clinical Center (CC).

ACTIVE NOT RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2025-01-01
Est. Completion 2025-12-31

What the Registry Record Tells You About NCT07226557

The ClinicalTrials.gov registry entry for NCT07226557 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Antimicrobial Drug Resistance appearing as the primary indexed condition, and to 0 interventions.

NCT07226557 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT07226557 about?

NCT07226557 is a clinical study titled "Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation". This study aims to compare 28-day mortality among patients with carbapenem resistant A. baumannii infections in two hypothetical target trials where patients receive 7 days of a cefiderocol-based treatment strategy or 7 days of a best available therapy treatment strategy.

What is the current status of trial NCT07226557?

This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 2025-01-01. Estimated completion is 2025-12-31.

What conditions does trial NCT07226557 study?

This clinical trial studies the following conditions: Antimicrobial Drug Resistance, Carbapenem Resistant Bacterial Infection, Acinetobacter Baumannii Infection.

Who is sponsoring clinical trial NCT07226557?

This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07226557 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Antimicrobial Drug Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.